Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03767725
Other study ID # Weihong Chen06082018
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 2, 2018
Est. completion date September 1, 2021

Study information

Verified date December 2018
Source Shenzhen Second People's Hospital
Contact Weihong Chen, M.D.
Phone 86-755-83366388
Email whitney-cindy@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of BCMA CART cells in treating patients with BCMA positive multiple myeloma that have not respond to chemotherapy and autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT). B-cell maturation antigen (BCMA), a cell surface protein expressed on mutiple maloma cells, has emerged as a very selective antigen to be targeted in novel immunotherpy for MM. Targeting postulated CD19 positive myeloma stem cells with anti-CD19 CAR-T cells is a novel approach to MM therapy.


Description:

This is multi-center, phase I trial that studies the side effects and best dose of BCMA CART cells in treating patients with BCMA positive multiple myeloma that have not respond to chemotherapy and autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT). B-cell maturation antigen (BCMA), a cell surface protein expressed on mutiple maloma cells , has emerged as a very selective antigen to be targeted in novel immunotherpy for MM. Targeting postulated CD19+ myeloma stem cells with anti-CD19 CAR-T cells is a novel approach to MM therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date September 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers No
Gender All
Age group 14 Years to 75 Years
Eligibility Inclusion Criteria:

- Have the capacity to give informed consent

- Have measurable disease by International Myeloma Working Group (IMWG) criteria based on one or more of the following findings:

- Serum M-protein >= 1 g/dL

- Urine M-protein >= 200 mg/24 hour

- Involved serum free light chain (sFLC) level >= 10 mg/dL with abnormal ?/? ratio

- Measurable biopsy-proven plasmacytomas (>= 1 lesion that has a single diameter >= 2 cm)

- Bone marrow plasma cells >= 30%

- Have a diagnosis of BCMA+ multiple myeloma (MM) (>= 5% BCMA+ by flow cytometry on CD138 co-expressing plasma cells obtained within 45 days of study enrollment); the MM diagnosis must be confirmed by internal pathology review of a fresh biopsy specimen at the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA)

- Have relapsed or treatment refractory disease with >= 10% CD138+ malignant plasma cells (IHC) on bone marrow (BM) core biopsy, either:

- Following autologous stem cell transplant (ASCT)

- Or, if a patient has not yet undergone ASCT, the individual must:

- Be transplant ineligible, due to age, comorbidity, patient choice, insurance reasons, concerns of rapidly progressive disease, and/or discretion of attending physician, and,

- Demonstrate disease that persists after > 4 cycles of induction therapy and that is double refractory (persistence/progression) after therapy with both a proteasome inhibitor and immunomodulatory drug (IMiD) administered either in tandem, or in sequence.

Exclusion Criteria:

- Active hepatitis B, hepatitis C at the time of screening

- Patients who are (human immunodeficiency virus [HIV]) seropositive

- Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis

- > 1 hospital admission for infection in prior 3 months

- Presence of acute or chronic graft-versus-host disease (GVHD) unless limited to skin involvement and managed with topical steroid therapy alone

- History of any one of the following cardiovascular conditions within the past 6 months: class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease

- History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid (CSF) within one week of enrollment) and have no evidence of new sites of CNS activity

- Pregnant or nursing women; NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy

- Use of any of the following:

- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis; physiologic replacement, topical, and inhaled steroids are permitted

- Allogeneic hematopoietic stem cell transplant (allo-HSCT) within 90 days of leukapheresis

- Cytotoxic chemotherapeutic agents within 1 week of leukapheresis; oral chemotherapeutic agents are allowed if at least 3 half-lives have elapsed prior to leukapheresis

- Low dose chemotherapy (e.g., bortezomib, lenalidomide, cyclophosphamide =< 300 mg/m^2) given after leukapheresis to maintain disease control must be stopped >= 7 days prior to initiation of lymphodepleting chemotherapy

- Lymphotoxic chemotherapeutic agents within 2 weeks of leukapheresis

- Experimental agents within 4 weeks of leukapheresis unless progression is documented on therapy and at least 3 half-lives have elapsed prior to leukapheresis

- Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the investigator; or unwillingness or inability to follow the procedures required in the protocol

- Absolute neutrophil count (ANC) < 1.0×10E9/L, Hemoglobin (Hgb) < 80 g/L, Platelet count < 50×10E9/L

- Active autoimmune disease requiring immunosuppressive therapy

- Major organ dysfunction defined as:

- Creatinine clearance < 20 ml/min

- Significant hepatic dysfunction (serum glutamic-oxaloacetic transaminase [SGOT] or serum glutamic-oxaloacetic transaminase (SGOT) or serum alanine aminotransferase (SALT) > 5×upper limit of normal; bilirubin > 3.0 mg/dL)

- Forced expiratory volume in 1 second (FEV1) of < 50% predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)

- Anticipated survival of < 3 months

- Contraindication to cyclophosphamide or fludarabine chemotherapy

- Patients with known AL subtype amyloidosis

Study Design


Intervention

Biological:
Treatment
Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.

Locations

Country Name City State
China Shenzhen Second People's Hospital,The first affiliated hospital of Shenzhen University Shenzhen Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen Second People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary No Dose-limiting toxicity No Dose-limiting toxicity up to 5 mouths after T cell infusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01435720 - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Phase 1/Phase 2
Recruiting NCT04094961 - Ixazomib + Pomalidomide + Dexamethasone In MM Phase 1/Phase 2
Recruiting NCT06068400 - Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Not yet recruiting NCT03706547 - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM Phase 1
Active, not recruiting NCT02970747 - Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Not yet recruiting NCT06411301 - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors Phase 1
Completed NCT01965353 - A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT05581875 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Phase 1/Phase 2
Terminated NCT03687125 - Tinostamustine Conditioning and Autologous Stem Cell Phase 1/Phase 2
Recruiting NCT06282978 - Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Phase 2
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Active, not recruiting NCT03030261 - Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Phase 2
Recruiting NCT04925193 - Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Completed NCT03136653 - A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma Phase 1/Phase 2